Parkinson’s disease treatment

Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability.Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease. Parkinson disease typically develops between the ages of 55 and 65 years and occurs in 1%–2% of people over the age of 60 years, rising to 3.5% at age 85–89 years. About 0.3% of the general population is affected, and the prevalence is higher among men than women, with a ratio of 1.5 to 1.0. Parkinson disease may be more common among white people than those of Asian or African descent; however, the data are conflicting. In 2011, the estimated number of people living with Parkinson disease in Canada had reached 85 200. By 2031, the projected number of people with this disease will double. Management remains complicated over the course of the disease and should be individualized based on the patient’s quality of life at each stage of disease. There have been many advancement in the management of Parkinson disease and ongoing research. Many options are now available. This review presents current treatment strategies and recommendations in managing motor and non-motor symptoms in the various stages of Parkinson disease. However, a few may eventually be diagnosed with Parkinson disease, based on clinical progression, imaging and genetic evidence and a positive response to levodopa. Treatment for Parkinson disease is limited with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of Parkinson disease such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of Parkinson disease pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of Parkinson disease without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of treatment for Parkinson is likely to be cured. Discovered in the 1960s, levodopa was the first symptomatic treatment for Parkinson disease, followed by the availability of dopamine agonists and monoamine oxidase B inhibitors. Until recently, the decision regarding which Parkinson’s treatment is initiated. It is nothing but the Magnetic resonance–guided focused ultrasound (MRgFUS) has been used extensively to ablate brain tissue in movement disorders, such as essential tremor. The treatment for Parkinson disease is done under Magnetic Resonance Imaging guidance which provides real-time imaging and temperature monitoring. Royal Care Super Speciality Hospital is the only Neuro-Care center in all of India, facilitated with expertise and technology that provides an MRgFUS (Magnetic Resonance guided Focused Ultrasound) therapy to Essential Tremors and Parkinson’s patients with tremors.

URL: https://mrgfus-royalcare.in/

https://www.facebook.com/royalcarecoimbatore/

Mrgfus RoyalCare is Parkinson's treatment, Best Neuroscience department in Coimbatore. Non- surgical treatment for Parkinson disease technique allows for incision-less Coimbatore. Url: https://mrgfus-royalcare.in/